Pharmacyte Biotech Inc. (PMCB) 0.1380 $PMCB
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
GlobeNewswire - Fri Feb 13, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here.
PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 11, 6:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
GlobeNewswire - Tue Feb 10, 8:07AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its international Diabetes Consortium has met to develop the path forward for the development of a novel treatment for insulin-dependent diabetes and that it has appointed Dr. Eva Maria Brandtner Director of Diabetes Program Development. The meeting brought together all members of the Consortium to plan the necessary preclinical studies that will be required to advance its Cell-in-a-Box live-cell encapsulated product for the treatment of diabetes. These studies will be used as a basis to prepare for future clinical trials in humans with diabetes. Dr. Brandtner will lead the planned work of the Consortium.
PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
Marketwired - Fri Feb 06, 8:01AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) -- How much would a cure for diabetes be worth? It's incalculable, but certainly many billions of dollars. Consider the insulin market alone is over $25 billion annually and projected to reach $40 Billion by 2018. Diabetes is a worldwide epidemic with over 350 million diabetes patients globally and growing.
PharmaCyte Biotech Officially Begins Development of Diabetes Treatment With First Preclinical Study
Marketwired - Wed Feb 04, 8:03AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) officially moved beyond the discussion of a diabetes treatment to planting its flag in the multi-billion dollar diabetes industry with its recent announcement that the company has started the first of its preclinical trials related to developing a diabetes treatment.
How High Will Cannabis Stocks Run This Year?
ACCESSWIRE - Wed Feb 04, 7:51AM CST
CORAL GABLES, FL / ACCESSWIRE / February 4, 2015 / Weed is now legal by popular vote in Washington, Colorado, Oregon, and Alaska's anticipated market is slated for full implementation in the near future. It's no surprise that people want to get in on the "ground floor" of the industry and though not everyone has the locale to open up their own storefront, the public markets have offered opportunity for investment into companies that do. Over recent weeks, may of these stocks have begun to rally and are piquing the interests of new and old pot traders market wide.
PharmaCyte Biotech Initiates First Preclinical Study of Its Encapsulated Cell Product for Novel Treatment of Diabetes
GlobeNewswire - Mon Feb 02, 9:06AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced in the Institute of Virology, Department of Pathobiology, at the University of Veterinary Medicine in Vienna, Austria. This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen cells, a human cell line engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body.
PharmaCyte Biotech's Partner Austrianova Opens New Facilities in Singapore
GlobeNewswire - Thu Jan 29, 9:04AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is a world-class biomedical sciences hub where key research organizations and institutes are located from around the globe. An "open house" event for guests to visit the new facilities in Singapore was held on January 29, 2015. The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, attended the opening ceremonies.
PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
GlobeNewswire - Mon Jan 26, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.
PharmaCyte Biotech (Formerly, Nuvilex): Where, Oh Where Did The Cash Flow Go...
Anthony Cataldo - at Seeking Alpha - Wed Jan 21, 8:06AM CST
PharmaCyte Biotech: A Re-Balanced, Statistical Look At Stock Promotions
Anthony Cataldo - at Seeking Alpha - Thu Jan 15, 1:59PM CST
PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
GlobeNewswire - Thu Jan 15, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 78.09 (+1.70)
PharmaCyte Biotech: A Balanced Look
Jack Banser - at Seeking Alpha - Mon Jan 12, 7:46AM CST
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 78.09 (+1.70)
Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
PharmaCyte Biotech (OTCQB: PHCB) formerly, Nuvilex Inc. (OTCQB: NVLX) as of January 8th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.
PharmaCyte Biotech Diabetes Consortium Member Publishes Review Article on Use of Genetic Engineering to Treat Diabetes
GlobeNewswire - Fri Feb 13, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies for the treatment of diabetes. The publication, titled "The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue," which was authored by a member of PharmaCyte Biotech's Diabetes Consortium, Prof. Ann M. Simpson and her colleagues at UTS, appeared in the prestigious Nature publishing group scientific journal Gene Therapy. This review can be located by clicking here. PharmaCyte Biotech Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Wed Feb 11, 6:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
PharmaCyte Biotech's International Diabetes Consortium Sets Path Forward to Develop Novel Treatment for Diabetes
GlobeNewswire - Tue Feb 10, 8:07AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, today announced that its international Diabetes Consortium has met to develop the path forward for the development of a novel treatment for insulin-dependent diabetes and that it has appointed Dr. Eva Maria Brandtner Director of Diabetes Program Development. The meeting brought together all members of the Consortium to plan the necessary preclinical studies that will be required to advance its Cell-in-a-Box live-cell encapsulated product for the treatment of diabetes. These studies will be used as a basis to prepare for future clinical trials in humans with diabetes. Dr. Brandtner will lead the planned work of the Consortium. PharmaCyte Biotech's Diabetes Treatment: How Would It Work?
Marketwired - Fri Feb 06, 8:01AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) -- How much would a cure for diabetes be worth? It's incalculable, but certainly many billions of dollars. Consider the insulin market alone is over $25 billion annually and projected to reach $40 Billion by 2018. Diabetes is a worldwide epidemic with over 350 million diabetes patients globally and growing.
PharmaCyte Biotech Officially Begins Development of Diabetes Treatment With First Preclinical Study
Marketwired - Wed Feb 04, 8:03AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB) officially moved beyond the discussion of a diabetes treatment to planting its flag in the multi-billion dollar diabetes industry with its recent announcement that the company has started the first of its preclinical trials related to developing a diabetes treatment.
How High Will Cannabis Stocks Run This Year?
ACCESSWIRE - Wed Feb 04, 7:51AM CST
CORAL GABLES, FL / ACCESSWIRE / February 4, 2015 / Weed is now legal by popular vote in Washington, Colorado, Oregon, and Alaska's anticipated market is slated for full implementation in the near future. It's no surprise that people want to get in on the "ground floor" of the industry and though not everyone has the locale to open up their own storefront, the public markets have offered opportunity for investment into companies that do. Over recent weeks, may of these stocks have begun to rally and are piquing the interests of new and old pot traders market wide.
PharmaCyte Biotech Initiates First Preclinical Study of Its Encapsulated Cell Product for Novel Treatment of Diabetes
GlobeNewswire - Mon Feb 02, 9:06AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced in the Institute of Virology, Department of Pathobiology, at the University of Veterinary Medicine in Vienna, Austria. This study is the first of a number of preclinical studies that will be performed. These studies are designed to test the safety, efficacy and dosing of Melligen cells, a human cell line engineered to produce and store insulin and secrete it at levels in proportion to the levels of glucose (blood sugar) in the human body. PharmaCyte Biotech's Partner Austrianova Opens New Facilities in Singapore
GlobeNewswire - Thu Jan 29, 9:04AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is a world-class biomedical sciences hub where key research organizations and institutes are located from around the globe. An "open house" event for guests to visit the new facilities in Singapore was held on January 29, 2015. The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, attended the opening ceremonies. PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
GlobeNewswire - Mon Jan 26, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks. PharmaCyte Biotech (Formerly, Nuvilex): Where, Oh Where Did The Cash Flow Go...
Anthony Cataldo - at Seeking Alpha - Wed Jan 21, 8:06AM CST
PharmaCyte Biotech: A Re-Balanced, Statistical Look At Stock Promotions
Anthony Cataldo - at Seeking Alpha - Thu Jan 15, 1:59PM CST
PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
GlobeNewswire - Thu Jan 15, 8:00AM CST
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST
GWPH: 78.09 (+1.70)
PharmaCyte Biotech: A Balanced Look
Jack Banser - at Seeking Alpha - Mon Jan 12, 7:46AM CST
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part III
Anthony Cataldo - at Seeking Alpha - Fri Jan 09, 12:29PM CST
GWPH: 78.09 (+1.70)
Pharmacyte Biotech Experiencing Marginal Success Still has Several Challenges in Coming Year: Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Jan 09, 6:00AM CST
PharmaCyte Biotech (OTCQB: PHCB) formerly, Nuvilex Inc. (OTCQB: NVLX) as of January 8th, 2015, based out of Silver Spring, Maryland, is a biotechnology firm leveraging its proprietary Cell-in-a-Box® to usher in new approaches to the treatment and management of several forms of cancer. The recent name change is to highlight the shift that PharmaCyte Biotech will now be operating as a purely biotechnology firm.
